2Engblom AC,Eriksson KS,Akerman KED. Glycine and GABA receptor-mediated chloridefluxes in synaptonenrosomes trom different parts of the rat brain. Brain Res, 1996,712: 74~83.
3Fern R,Wasman SG,Ranson BR. Modulation of anoxic injury in CNS white matter byadenosine and interaction between adenosine and GABA. J Neurophysiol, 1995,72: 2609 ~2616.
4Easton JD. Current advances in the management of stroke. Neu rology,1998,51 (suppl3) :S1~S2.
5Dyker AG,Lees KR. Duration of neuroprotective treatment for ischemic strock,Strock, 1998,29: 535 ~ 542.
6Muir KW, Lees KR. Dose optimization of intravenous magne sium sulfate after acutestrock. Strock, 1998,29: 918 ~923.
8Onal MZ,Fisher M. Acute ischemic stroke therapy. Eur Neurol, 1997,38:141~154.
9Giroux C,Scatton B,Ischemic stroke:treatment on the horizon, Eur Neurol,1996,36(1):61~64.
10Barinaga M,Finding new drugs to treat stroke. Science, 1996, 272 (3): 665-666.
二级参考文献1
1V. Kraaier,A. C. Huffelen,G. H. Wieneke,J. M. Keppel Hesselink. Nimodipine tested in a human model of cerebral ischaemia[J] 1991,European Journal of Clinical Pharmacology(1):17~21